Some heterogeneity factors affecting the B-type natriuretic peptides outcome: A meta-analysis

Clinical Chemistry and Laboratory Medicine

Volumn 46, Issue 12, 2008, Pages 1687-1695

  Mastandrea, Paolo ^a  

^a Azienda Ospedaliera   (Italy)

Author keywords

Brain natriuretic peptide; Meta analysis; Population groups

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BRAIN NATRIURETIC PEPTIDE;

ARTICLE; DISEASE SEVERITY; HEART FAILURE; HUMAN; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SENSITIVITY AND SPECIFICITY;

HEART FAILURE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PROGNOSIS;

EID: 57449092879     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2008.348     Document Type: Article

References (77)

1. Clerico A, Emdin M. Natriuretic peptides. Milan, Italy: Springer-Verlag, 2006.
2. Richards M, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. Comparison of B-type natriuretic peptides for assessment of cardiac function and prognosis in stable ischemic heart disease. J Am Coll Cardiol 2006;47:52-60.
3. Januzzi JL, van Kimmenade R, Lainchbury J, Bayes-Genis A, Ordonez-Llanos J, Santalo-Bel M, et al. NT-proBNP testing for diagnosis and short-term prognosis in acute destabilized heart failure: an international pooled analysis of 1256 patients. Eur Heart J 2006;27:330-7.
4. Araujo JP, Azevedo A, Lourenco P, Rocha-Goncalves F, Ferreira A, Bettencourt P. Intraindividual variation of NTproBNP in patients with stable heart failure. Am J Cardiol 2006;98:1248-50.
5. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Diagnostic accuracy of B type natriuretic peptide and amino-terminal proBNP in the emergency diagnosis of heart failure. Heart 2005;91:606-12.
6. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, et al. Renal function, congestive heart failure and amino-terminal pro-brain natriuretic peptide measurement. J Am Coll Cardiol 2006;47:91-7.
7. St Peter JV, Hartley GG, Murakami MM, Apple FS. BNP and NT-proBNP in obese patients without heart failure: relationship to body mass index and gastric bypass surgery. Clin Chem 2006;52:680-5.
8. Daniels LB, Clopton P, Bhalla V, Krishnaswamy P, Nowak RM, McCord J, et al. How obesity affects the cut-points for B-type natriuretic peptide in the diagnosis of acute heart failure: results from the Breathing Not Properly Multinational Study. Am Heart J 2006;151:1006-12.
9. Hirata Y, Matsumoto A, Aoyagi T, Yamaoki K, Komuro I, Suzuki T, et al. Measurement of plasma brain natriuretic peptide level as a guide for cardiac overload. Cardiovasc Res 2001;51:585-91.
10. Luchner A, Burnett J Jr, Jougasaki M, Hense HW, Heid IM, Muders F, et al. Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population. J Hypertens 2000;18:1121-8.
11. Hogenhuis J, Voors AA, Jaarsma T, Hoes AW, Hillege HL, Kragten JA, et al. Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure. Eur J Heart Fail 2007;9:787-94.
12. Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000;6:194-200.
13. Januzzi JL, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, et al. The N-terminal proBNP investigation of dyspnea in the Emergency Department (PRIDE) study. Am J Cardiol 2005;95:948-54.
14. Ray P, Arthaud M, Lefort Y, Birolleau S, Beigelman C, Riou B. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med 2004;30:2230-6.
15. Ioannidis JP, Lau J. Heterogeneity of the baseline risk within patient populations of clinical trials: a proposed evaluation algorithm. Am J Epidemiol 1998;148:1117-26.
16. Clerico A, Fontana M, Zyw L, Passino C, Emdin M. Comparison of the diagnostic accuracy of BNP and NT-proBNP immunoassays in chronic and acute heart failure: a systematic review. Clin Chem 2007;53:813-22.
17. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK. Reliability of N-terminal proBNP assay in diagnosis of left ventricular systolic dysfunction within representative and high risk populations. Heart 2004;90:866-70.
18. Bassan R, Potsch A, Maisel A, Tura B, Villacorta H, Viegas Nogueira M, et al. B-type natriuretic peptide: a novel early blood marker of acute myocardial infarction in patients with chest pain and no ST-segment elevation. Eur Heart J 2005;26:234-40.
19. Nishikimi T, Mori Y, Ishimura K, Tadokoro K, Yagi H, Yabe A, et al. Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. Am J Med 2004;116:517-23.
20. Rana BS, Davies JI, Band MM, Pringle S, Morris AD, Struthers AD. B-type natriuretic peptide can detect silent myocardial ischaemia in asymptomatic type 2 diabetic patients. Heart 2006;92:916-20.
21. Win HK, Chang SM, Ralzner M, Shah G, Basky FA, Desai U, et al. Percent change in B-type natriuretic peptide levels during treadmill exercise as a screening test for exercise-induced myocardial ischemia. Am Heart J 2005;150:695-700.
22. Foote RS, Pearlman JD, Siegel AH, Yeo KT. Detection of exercise-induced ischemia by changes in B-type natriuretic peptides. J Am Coll Cardiol 2004;44:1980-7.
23. Lim P, Monin JL, Monchi M, Garot J, Pasquet A, Hittinger L, et al. Predictors of outcome in patients with severe aortic stenosis and normal left ventricular function: role of B-type natriuretic peptide. Eur Heart J 2004;25:2048-53.
24. Takase H, Toriyama T, Sugiura T, Ueda R, Dohi Y. Brain natriuretic peptide in the prediction of recurrence of angina pectoris. Eur J Clin Invest 2004;34:79-84.
25. Funck F, Jourdain P, Guillard N, Fulla Y, Sadeg N, Bellorini M, et al. Utilité du dosage du BNP aux urgencies chez les patients suspects d'angor instable avec ECG normal. Arch Mal Coeur Vaiss 2003;96:181-5.
26. Bhalla V, Isakson S, Bhalla MA, Lin JP, Clopton P, Gardetto N, et al. Diagnostic ability of B-type natriuretic peptide and impedance cardiography: testing to identify left ventricular dysfunction in hypertensive patients. Am J Hypertens 2005;18(Suppl. 2):73-85.
27. Hammerer-Lercher A, Ludwig W, Falkensammer G, Muller S, Neubauer E, Puschendorf B, et al. Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 2004;50:1174-83.
28. Bibbins-Domingo K, Ansari M, Schiller NB, Massie B, Whooley MA. Is B-type natriuretic peptide a useful screening test for systolic or diastolic dysfunction in patients with coronary disease? Data from the heart and soul study. Am J Med 2004;116:509-16.
29. Mallamaci F, Zoccali C, Tripepi G, Benedetto FA, Parlongo S, Cataliotti A, et al. Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int 2001;59:1559-66.
30. Epshteyn V, Morrison K, Krishnaswamy P, Kazanegra R, Clopton P, Mudaliar S, et al. Utility of B-type natriuretic peptide (BNP) as a screen for left ventricular dysfunction in patients with diabetes. Diabetes Care 2003;26:2081-7.
31. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Biochemical diagnosis of impaired left ventricular ejection fraction - comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino-terminal proBNP (NT-proBNP). Clin Chem Lab Med 2004;42:159-63.
32. Smith H, Pickering RM, Struthers A, Simpson I, Mant D. Biochemical diagnosis of ventricular dysfunction in elderly patients in general practice: observational study. Br Med J 2000;320:906-8.
33. Prontera C, Emdin M, Zucchelli GC, Ripoli A, Passino C, Clerico A. Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay for the N-terminal fragment of the pro-peptide of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. Clin Chem Lab Med 2004;42:37-44.
34. Redfield M, Rodeheffer JR, Jacobsen JS, Mahoney DW, Bailey KR, Burnett JC. Plasma brain natriuretic peptide to detect preclinical ventricular systolic or diastolic dysfunction. Circulation 2004;109:3176-81.
35. Wei T, Zeng C, Chen L, Chen Q, Zhao R, Lu G, et al. Bedside tests of B-type natriuretic peptide in the diagnosis of left ventricular diastolic dysfunction in hypertensive patients. Eur J Heart Fail 2005;7:75-9.
36. Niinuma H, Nakamura M, Hiromori K. Plasma B-type natriuretic peptide measurement in a multiphasic health screening program. Cardiology 1998;90:89-94.
37. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:347-51.
38. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, et al. Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community. J Am Coll Cardiol 2006;47:345-53.
39. Hutcheon SD, Gillespie ND, Struthers AD, McMurdo M. B-type natriuretic peptide in the diagnosis of cardiac disease in elderly day hospital patients. Age Ageing 2002;31:295-301.
40. Knudsen CW, Omland T, Clopton P, Westheim A, Wu A, Duc P, et al. Impact of atrial fibrillation on the diagnostic performance of B-type natriuretic peptide concentration in dyspnea patients. J Am Coll Cardiol 2005;46:838-44.
41. Ray P, Arthaud M, Birolleau S, Isnard R, Lefort Y, Boddaert J, et al. Comparison of brain natriuretic peptide and probrain natriuretic peptide in the diagnosis of cardiogenic pulmonary edema in patients aged 65 and older. J Am Geriatr Soc 2005;53:643-8.
42. McDonagh AT, Robb SD, Murdoch DR, Morton JJ, Ford I, Morrison CE, et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
43. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM. Brain natriuretic peptide and N-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003;42:728-35.
44. Steg PhG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005;128:21-9.
45. McCullough PA, Nowak RM, McCord J, Hollander JE, Herrmann HC, Steg PhG, et al. B-type natriuretic peptide and clinical judgement in emergency diagnosis of heart failure. Analysis from Breathing Not Properly Multinational study. Circulation 2002;106:416-22.
46. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc Ph, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002;347:161-7.
47. Gegenhuber A, Struck J, Poelz W, Pacher R, Morgenthaler NG, Bergmann A, et al. Midregional pro-A-type natriuretic peptide measurements for diagnosis of acute destabilized heart failure in short-of-breath patients: comparison with B-type natriuretic peptide (BNP) and amino-terminal proBNP. Clin Chem 2006;52:827-31.
48. Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, et al. BNP and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med 2004;170:360-5.
49. Morrison LK, Harrison A, Krishnaswamy P, Kazanegra R, Clopton P, Maisel A. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J Am Coll Cardiol 2002;39:202-9.
50. Gegenhuber A, Mueller T, Dieplinger B, Lenz K, Poelz W, Haltmayers M. Plasma B-type natriuretic peptide in patients with pleural effusions. Chest 2005;128:1003-9.
51. Dao Q, Krishnaswamy P, Kazanegra R, Harrison H, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001;37:379-85.
52. Weber M, Dill T, Arnold R, Rau M, Ekinci O, Müller KD, et al. N-terminal B-type natriuretic peptide predicts extent of coronary artery disease and ischemia in patients with stable angina pectoris. Am Heart J 2004;148:612-20.
53. Hobbs FD, Davis RC, Roalfe AK, Hare R, Davies MK, Kenkre JR. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br Med J 2002;324:1498-502.
54. Luchner A, Hengstenberg C, Hannelore L, Buchner S, Schunkert H, Riegger GA, et al. NT-proBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J Card Fail 2005;11:S21-7.
55. Kragelund C, Grønning B, Omland T, Køber L, Strande S, Steffensen R, et al. Is N-terminal pro B-type natriuretic peptide a useful screening test for angiographic findings in patients with stable coronary disease? Am Heart J 2006;151:712.e1-7.
56. Galasko GI, Lahiri A, Barnes S, Collinson P, Senior R. What is the normal range for N-terminal pro-brain natriuretic peptide? How well does this normal range screen for cardiovascular disease? Eur Heart J 2005;26:2269-76.
57. Mueller T, Gegenhuber A, Poelz W, Haltmayer M. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. Clin Chem 2003;49:976-9.
58. Groenning BA, Raymond I, Hildebrandt PR, Nilsson JC, Baumann M, Pedersen F. Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 2004;90:297-303.
59. Luchner A, Hengstenberg C, Lowel H, Trawinski J, Baumann M, Riegger GA, et al. N-terminal pro-brain natriuretic peptide after myocardial infarction: a marker of cardio-renal function. Hypertension 2002;39:99-104.
60. Ng LL, Loke IW, Davies JE, Geeranavar S, Khunti K, Stone MA, et al. Community screening for left ventricular systolic dysfunction using plasma and urinary natriuretic peptides. J Am Coll Cardiol 2005;45:1043-50.
61. Kucher N, Printzen G, Doernhofer T, Windecker S, Meier B, Hess OM. Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 2003;107:1576-8.
62. Bay M, Kirk V, Parner J, Hassager C, Nielsen H, Krogsgaard K, et al. NT-proBNP: a new diagnostic screening tool to differentiate between patients with normal and reduced left ventricular systolic function. Heart 2003;89:150-4.
63. Irwig L, Macaskill P, Glasziou P, Fahey M. Meta-analytic methods for diagnostic test accuracy. J Clin Epidemiol 1995;48:119-30.
64. Wang MC, Bushman BJ. Integrating results through meta-analytic review using SAS software. SAS Institute Inc., Cary, NC, USA,1999.
65. D'Agostino RB, Balanger A. A suggestion for using powerful and informative tests of normality. Am Statistician 1990;44:316-21.
66. Egger M, Davey-Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Br Med J 1997;315:629-34.
67. Cooper H, Hedges LV, editors. The handbook of research synthesis. New York: Russell Sage Foundation, 1994.
68. Borenstein M, Hedges L, Rothstein A. Introduction to meta-analysis. New York: Wiley. In press.
69. McLachlan GJ, Krishnan T. The expectation-maximization algorithm and extensions, 2nd edn. New York: Wiley, 2008.
70. Thomas MD, Fox KF, Coats AJ, Sutton GC. The epide miological enigma of heart failure with preserved systolic function. Eur J Heart Fail 2004;6:125-36.
71. Steg PG, Joubin L, McCord J, Abraham WT, Hollander JE, Omland T, et al. B-type natriuretic peptide and echocardiographic determination of ejection fraction in the diagnosis of congestive heart failure in patients with acute dyspnea. Chest 2005;128:21-9.
72. Mak GS, DeMaria A, Clopton P, Maisel AS. Utility of B-natriuretic peptide in the evaluation of left ventricular diastolic function: comparison with tissue Doppler imaging records. Am Heart J 2004;148:895-902.
73. Brenner H, Gefeller O. Variation of sensitivity, specificity, likelihood ratios and predictive values with disease prevalence. Stat Med 1997;16:981-91.
74. Ioannidis JP. Differentiating bias from genuine heterogeneity: distinguishing artifactual from substantive effects. In: Rothstein HR, Sutton AJ, Borenstein M, editors. Publication bias in meta-analysis. New York: Wiley, 2005:287-302.
75. Clerico A, Caprioli R, Del Ry S, Giannessi D. Clinical relevance of cardiac natriuretic peptides measured by means of competitive and non-competitive immunoassay methods in patients with renal failure on chronic hemodialysis. J Endocrinol Invest 2001;24:24-30.
76. Vickery S, Price CP, John RI, Abbas NA, Webb MC, Kempson ME, et al. B-type natriuretic peptide and amino-terminal proBNP in patients with chronic kidney disease: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005;46:610-20.
77. Racek J, Kralova H, Trefil L, Rajd D, Eiselt J. Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract 2006;103:c162-72.